Study EvAluating Genotypes While Using Lucentis 2

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Ability to provide written informed consent and comply with the study assessments for the full duration of the study.

• Age > 50 years.

• Treatment naïve (study eye only) AMD patients that are determined to be candidates for ranbizumab.

• Visual acuity 20/32 to 20/230.

Exclusion Criteria:

• Pregnancy

• Prior enrollment in the study

• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

• Previous therapy in study eye for AMD or other retinal disease which may be used in the treatment of AMD.

• Any other condition that the investigator believes would pose a significant hazard to the subject if on-label ranibizumab were prescribed

• Any participation in another simultaneous medical investigation or trial for AMD *Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma)